Company: Axial Therapeutics, Inc.
Job title: Vice President, Head Of Preclinical Research & Development
Development of AX-5006 a Small Molecule Inhibitor of CsgA Aggregation As a Potential Disease Modifying Treatment for Parkinson’s Disease 12:30 pm
Understanding the role of the microbiome in Parkinson’s Disease Outlining the rationale for targeting CsgA as a therapeutic for Parkinson’s Disease Revealing the preclinical efficacy, pharmacokinetics, and tolerability profile of AX-5006Read more
day: Conference Day 1 Track A AM 1